Research Grade Sutimlimab

Catalog No.

DHC43601

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

C1 esterase, Complement C1s subcomponent, C1S, Complement component 1 subcomponent s

Concentration

3.07 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P09871

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BIVV009, IPN-009, TNT009, CAS: 2049079-64-1

Clone ID

Sutimlimab

Autoimmune hemolytic anemia, PMID: 30504336

Antibodies to watch in 2020, PMID: 31847708

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial, PMID: 30559259

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1, PMID: 33261023

Novel insights into the treatment of complement-mediated hemolytic anemias, PMID: 31523413

Sutimlimab in Cold Agglutinin Disease, PMID: 33826820

C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro, PMID: 30635392

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway, PMID: 29737533

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program, PMID: 32176765

2019 ASH Annual Meeting, PMID: 31859224

Cold agglutinin disease: current challenges and future prospects, PMID: 31114413

How I treat cold agglutinin disease, PMID: 33512410

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid, PMID: 31229501

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features, PMID: 32685889

Successful treatment of refractory cold agglutinin syndrome using fixed duration daratumumab, bortezomib and dexamethasone with a sutimlimab bridge., PMID:40400475

Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab., PMID:39503157

Autoimmune haemolytic anaemias., PMID:39487134

Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease., PMID:39402301

Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy., PMID:39371250

[New drugs for the treatment of primary immune thrombocytopenia]., PMID:39358266

Sutimlimab for Cold Agglutinin Disease., PMID:39328891

Adult-onset severe paroxysmal cold hemoglobinuria after COVID-19 successfully treated with sutimlimab., PMID:39304597

[The treatment strategies of autoimmune hemolytic anemia]., PMID:39134500

Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension., PMID:39114274

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B., PMID:39091672

Efficacy of sutimlimab for cold agglutinin disease in a patient on chronic hemodialysis., PMID:39017802

Diagnosis and management of Evans syndrome in adults: first consensus recommendations., PMID:38968944

[Cold agglutinin disease: pathology, diagnosis, and treatment]., PMID:38960651

The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease., PMID:38872338

Röth A, Broome CM, Barcellini W, et al. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Adv. 2023;7(19):5890-5897., PMID:38809539

Cost-effectiveness of sutimlimab in cold agglutinin disease., PMID:38733355

[Sutimlimab for cold agglutinin disease, a newcomer among complement inhibitors in immunohematology]., PMID:38719668

Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study., PMID:38519606

COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab., PMID:38385639

Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease., PMID:38148014

Antibody based therapeutics for autoimmune hemolytic anemia., PMID:37874225

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps., PMID:37795092

[Novel therapeutic agents for hemolytic anemia]., PMID:37793862

Novel therapeutics and future directions for refractory immune thrombocytopenia., PMID:37735554

Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up., PMID:37459203

[Novel anti-complement therapeutics for hemolytic anemia]., PMID:37407469

Molecular pharmacology in complement-mediated hemolytic disorders., PMID:37308291

Complement-directed therapy for cold agglutinin disease: sutimlimab., PMID:37256550

Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease., PMID:37246953

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease., PMID:37164370

Sutimlimab for the Treatment of Cold Agglutinin Disease., PMID:37153870

Monoclonal antibodies for treatment of cold agglutinin disease., PMID:37128907

Rise of the planet of rare anemias: An update on emerging treatment strategies., PMID:36698833

Recent progress in ITP treatment., PMID:36622549

Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis., PMID:36476151

Antibodies to watch in 2023., PMID:36472472

Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study., PMID:36403132

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease., PMID:36322823

Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?, PMID:36127205

A virtuosic CADENZA played by sutimlimab., PMID:36048476

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study., PMID:35999387

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia., PMID:35973190

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?, PMID:35946351

Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia., PMID:35747120

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial., PMID:35687757

Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial., PMID:35655238

Sutimlimab: First Approval., PMID:35412113

Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia., PMID:35282954

Document Download

Research Grade Sutimlimab.pdf